Social Behavior – Page 10

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

7 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues

Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition

7 months ago talkbio0Tagged Acquisition, Catalent, competition, Holdings, pharmaceutical market, Revenue Estimates, United States Federal Trade Commission

Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust

Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents

7 months ago talkbio0Tagged Age related macular degeneration, Agreement, Antibodies, Bispecific, Cancer Therapeutic Procedure, Clinical Trials, Exudative age-related macular degeneration, Neovascular, Royalty, Vascular Endothelial Growth Factor A

Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.

FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment

7 months ago talkbio0Tagged authorization, Desiccation, Glycogen storage disease type II, LumiThera, photobiomodulation, United States Food and Drug Administration, Valeda Light Delivery System

FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera

Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform

7 months ago talkbio0Tagged 2024, Biopharma, Donald Trump, Drug Industry, Drug Pricing Reform, Inflation, Kamala Harris, Mediation, Medicare, presidential election, Prices

Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.